| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Verapamil GC-MS (Non-derivatized) - 70eV, Positive | splash10-0cdu-4391500000-cd36ebd65bc8c7765961 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Verapamil GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Verapamil GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Verapamil GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Verapamil GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-0udi-3519000000-b5e0b9e0caac5cb57222 | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Verapamil Quattro_QQQ 10V, Positive-QTOF (Annotated) | splash10-004l-0702900000-6a46ea2d5eed6d8b01eb | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Verapamil Quattro_QQQ 25V, Positive-QTOF (Annotated) | splash10-0006-4109800000-80d342090a0be3344e82 | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Verapamil Quattro_QQQ 40V, Positive-QTOF (Annotated) | splash10-054w-0954400000-2def387c7c93ab211423 | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Verapamil LC-ESI-QQ (API3000, Applied Biosystems) 10V, Positive-QTOF | splash10-0a4i-0000900000-4cde9a4b3a4f83d16afc | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Verapamil LC-ESI-QQ (API3000, Applied Biosystems) 20V, Positive-QTOF | splash10-0a4i-0000900000-980b47834e505d54a0e6 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Verapamil LC-ESI-QQ (API3000, Applied Biosystems) 30V, Positive-QTOF | splash10-066r-0902800000-ae024239c46b33917426 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Verapamil LC-ESI-QQ (API3000, Applied Biosystems) 40V, Positive-QTOF | splash10-014i-0901000000-81d1159b3102cff76218 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Verapamil LC-ESI-QQ (API3000, Applied Biosystems) 50V, Positive-QTOF | splash10-014i-0900000000-d9c344fee7b45b4030e6 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Verapamil LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positive-QTOF | splash10-0gb9-0914000000-070bdb975910e9aae99c | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Verapamil LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positive-QTOF | splash10-03di-0390000000-f41d80462c5d06c4f001 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Verapamil LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positive-QTOF | splash10-0097-2980000000-9a2ab0bcab33f7eaac6b | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Verapamil LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positive-QTOF | splash10-0uxr-0900000000-252a9989a8511cb2db80 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Verapamil LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positive-QTOF | splash10-0f79-0900000000-4fd6ca2c6c19c3bbf8f0 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Verapamil LC-ESI-QTOF , positive-QTOF | splash10-0a4i-0000900000-4365a47b2dc2f86bb272 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Verapamil LC-ESI-QTOF , positive-QTOF | splash10-0a4i-0000900000-e6a2b357160bf5b92c22 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Verapamil LC-ESI-QTOF , positive-QTOF | splash10-066r-0902400000-d8eac2ccd0a767c7e432 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Verapamil LC-ESI-QTOF , positive-QTOF | splash10-014i-0901000000-688f3c2345c5d9ccb8a5 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Verapamil LC-ESI-QTOF , positive-QTOF | splash10-014i-0900000000-cd09f8a2be876936f662 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Verapamil LC-ESI-ITFT , positive-QTOF | splash10-0uxr-0918000000-76641dd6dbc5cb05e79a | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Verapamil 10V, Positive-QTOF | splash10-0a4i-0010900000-c5883de78bb084688acb | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Verapamil 20V, Positive-QTOF | splash10-014i-0573900000-c95a634d7e2ecac924b7 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Verapamil 40V, Positive-QTOF | splash10-014i-1962200000-5e5b0f3f1481cfd4da52 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Verapamil 10V, Negative-QTOF | splash10-0udi-0000900000-44ab3d7fdbe57d5f189d | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Verapamil 20V, Negative-QTOF | splash10-0f79-0031900000-562635f25a21f2cbad9f | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Verapamil 40V, Negative-QTOF | splash10-0080-0192300000-aada67fc0f3e7f227e44 | 2017-07-26 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Experimental 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | 2012-12-05 | Wishart Lab | View Spectrum |
| Show more...
---|
General References | - Takeda H, Yamazaki Y, Akahane M, Igawa Y, Ajisawa Y, Nishizawa O: Role of the beta(3)-adrenoceptor in urine storage in the rat: comparison between the selective beta(3)-adrenoceptor agonist, CL316, 243, and various smooth muscle relaxants. J Pharmacol Exp Ther. 2000 Jun;293(3):939-45. [PubMed:10869395 ]
- Wang YH, Jones DR, Hall SD: Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71. Epub 2005 Feb 2. [PubMed:15689501 ]
- Byerly WG, Hartmann A, Foster DE, Tannenbaum AK: Verapamil in the treatment of maternal paroxysmal supraventricular tachycardia. Ann Emerg Med. 1991 May;20(5):552-4. [PubMed:2024796 ]
- Miller MR, Withers R, Bhamra R, Holt DW: Verapamil and breast-feeding. Eur J Clin Pharmacol. 1986;30(1):125-6. [PubMed:3709626 ]
- Takano A, Kusuhara H, Suhara T, Ieiri I, Morimoto T, Lee YJ, Maeda J, Ikoma Y, Ito H, Suzuki K, Sugiyama Y: Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. J Nucl Med. 2006 Sep;47(9):1427-33. [PubMed:16954549 ]
- Fakih H, MacLusky N, DeCherney A, Wallimann T, Huszar G: Enhancement of human sperm motility and velocity in vitro: effects of calcium and creatine phosphate. Fertil Steril. 1986 Nov;46(5):938-44. [PubMed:3781011 ]
- Suzuki S, Nishimaki-Mogami T, Tamehiro N, Inoue K, Arakawa R, Abe-Dohmae S, Tanaka AR, Ueda K, Yokoyama S: Verapamil increases the apolipoprotein-mediated release of cellular cholesterol by induction of ABCA1 expression via Liver X receptor-independent mechanism. Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):519-25. Epub 2004 Jan 15. [PubMed:14726413 ]
- Glusa E: Effect of verapamil on platelet aggregation. Folia Haematol Int Mag Klin Morphol Blutforsch. 1988;115(4):469-73. [PubMed:2465955 ]
- Ceccato A, Chiap P, Hubert P, Toussaint B, Crommen J: Automated determination of verapamil and norverapamil in human plasma with on-line coupling of dialysis to high-performance liquid chromatography and fluorometric detection. J Chromatogr A. 1996 Oct 25;750(1-2):351-60. [PubMed:8938391 ]
- Nanni G, Panocchia N, Tacchino R, Foco M, Piccioni E, Castagneto M: Increased incidence of infection in verapamil-treated kidney transplant recipients. Transplant Proc. 2000 May;32(3):551-3. [PubMed:10812109 ]
- Affolter H, Burkard WP, Pletscher A: Verapamil, an antagonist at 5-hydroxytryptamine receptors of human blood platelets. Eur J Pharmacol. 1985 Jan 22;108(2):157-62. [PubMed:3156755 ]
- Rumiantsev DO, Piotrovskii VK, Riabokon' OS, Metelitsa VI: [Comparison of the verapamil concentration of human blood serum and saliva]. Farmakol Toksikol. 1987 Jan-Feb;50(1):85-9. [PubMed:3556560 ]
- Gramatte T, Oertel R: Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin Pharmacol Ther. 1999 Sep;66(3):239-45. [PubMed:10511059 ]
- Hsiao P, Sasongko L, Link JM, Mankoff DA, Muzi M, Collier AC, Unadkat JD: Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. J Pharmacol Exp Ther. 2006 May;317(2):704-10. Epub 2006 Jan 13. [PubMed:16415090 ]
- von Richter O, Greiner B, Fromm MF, Fraser R, Omari T, Barclay ML, Dent J, Somogyi AA, Eichelbaum M: Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clin Pharmacol Ther. 2001 Sep;70(3):217-27. [PubMed:11557909 ]
- Narang PK, Blumhardt CL, Doran AR, Pickar D: Steady-state cerebrospinal fluid transfer of verapamil and metabolites in patients with schizophrenia. Clin Pharmacol Ther. 1988 Nov;44(5):550-7. [PubMed:3180637 ]
- Szymanski W, Skublicki S, Jankowski A, Kotzbach R: [Pharmacokinetic investigations of verapamil used as a concomitant drug in treatment of premature labor]. Ginekol Pol. 1992 Apr;63(4):166-71. [PubMed:1303922 ]
- Wang YH, Jones DR, Hall SD: Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66. [PubMed:14744949 ]
- Dumestre-Toulet V, Cirimele V, Gromb S, Belooussoff T, Lavault D, Ludes B, Kintz P: Last performance with VIAGRA: post-mortem identification of sildenafil and its metabolites in biological specimens including hair sample. Forensic Sci Int. 2002 Mar 28;126(1):71-6. [PubMed:11955836 ]
- Bauer LA, Horn JR, Maxon MS, Easterling TR, Shen DD, Strandness DE Jr: Effect of metoprolol and verapamil administered separately and concurrently after single doses on liver blood flow and drug disposition. J Clin Pharmacol. 2000 May;40(5):533-43. [PubMed:10806607 ]
- Hofer CA, Smith JK, Tenholder MF: Verapamil intoxication: a literature review of overdoses and discussion of therapeutic options. Am J Med. 1993 Oct;95(4):431-8. [PubMed:8213877 ]
- Bellamy WT: P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol. 1996;36:161-83. [PubMed:8725386 ]
| Show more...
---|